TPI and HollandBio Partner for Animal-Free Biotech Innovation
Netherlands, Wednesday, 29 January 2025.
The partnership between TPI and HollandBio aims to accelerate sustainable animal-free biotech solutions, enhancing ethical practices in the Netherlands’ biotech sector.
A Milestone for Medical Research Innovation
This collaboration marks a significant development in medical and healthtech innovation, as TPI (Transitie Proefdiervrije Innovatie) welcomes HollandBio, the Netherlands’ biotechnology industry association, as its newest partner [1]. The partnership focuses primarily on advancing animal-free testing methods for pharmaceutical development and medical research [2]. While current drug development still requires animal testing, biotechnology innovations are increasingly providing alternative disease models that not only prevent unnecessary animal suffering but also offer superior predictive value compared to traditional animal testing [2].
Advanced Testing Technologies
The partnership promotes cutting-edge testing alternatives including 3D cell culture, organoids, and organ-on-a-chip technologies [2]. These innovative approaches are revolutionizing the development process for biochemical substances, pharmaceuticals, and food products while simultaneously reducing dependence on animal testing [2]. HollandBio, representing the Dutch biotech sector, will play a crucial role in accelerating the implementation of these animal-free models in practical applications [1].
Leadership and Implementation
The collaboration will be steered by key figures from HollandBio, with Wieteke Wouters joining TPI’s core group and Britt van de Ven contributing her expertise as Health Program Manager in the transition group [1][2]. This partnership aims to position the Netherlands as a catalyst for international transition towards animal-free innovations [2]. The initiative aligns with TPI’s mission of ‘better prediction without animal testing’ and brings together eleven partners in total to accelerate this transition [1].